YOUHAI H. CHEN
Dean of Faculty of Pharmaceutical Sciences,Shenzhen Institutes of Advanced Technology (SIAT),
Chinese Academy of Sciences (CAS)
Director of Center for Cancer Immunology
Address: 1068 Xueyuan Avenue, Shenzhen University Town, Xili, Nanshan, Shenzhen 518055, China.
Email: yh.chen@siat.ac.cn
Telephone: 0755-26912104
Postcode: 518055
Research Areas
Cancer, inflammation, immunity
Education
1989-09--1993-05 University of Manitoba,Ph.D. Immunology
1983-09--1986-07 Shandong University,M.Sc. Immunology
1978-09--1983-07 Shandong University, Bachelor of Medicine
Experience
Work Experience
2021-Present: Dean of Faculty of Pharmaceutical Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences
2021-Present: Director of Center for Cancer Immunology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
2008-2020: Tenured Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
2001-2008: Tenured Associate Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
2021-Present: Director of Center for Cancer Immunology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
2008-2020: Tenured Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
2001-2008: Tenured Associate Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
Teaching Experience
Honors & Distinctions
Medical Research Council (MRC) Fellowship Award, 1990-1993
Travel Award, Canadian Society for Immunology, 1992
Medical Research Council (MRC) Scholar Award, 1994-1995
M.A. hon., Arts, University of Pennsylvania, Philadelphia, PA, 2001
Lady Barbara Colyton Prize for Autoimmune Research, 2002
Elected Member, Henry Kunkel Society, 2008
Publications
Papers
1. Yaohui Wang, Hailong Zhang, Zhizeng Wang, Yinxiang Wei,… Youhai H Chen*, Yuanfang Ma*. Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats. Sci Transl Med. 12 (540): eaaw3172, 2020.
2. Jason R Goldsmith, Nina Spitofsky, Ali Zamani, Ryan Hood,…Youhai H Chen. TNFAIP8 controls murine intestinal stem cell homeostasis and regeneration by regulating microbiome-induced Akt signaling. Nat Commun. 22;11(1):2591, 2020.
3. Ting Li, Xinyuan Li, Ali Zamani, Wei Wang, Chin-Nien Lee, Mingyue Li, George Luo, Emily Eiler, Honghong Sun, Sankar Ghosh, Jian Jin, Ramachandran Murali, Qingguo Ruan, Weiyun Shi and Youhai H. Chen. c-Rel is a myeloid checkpoint for cancer immunotherapy. Nature Cancer 1: 507-517, 2020.
4. Dehong Yan, Jinghui Wang, Honghong Sun, Ali Zamani, Honglin Zhang, Weihong Chen, Aifa Tang, Qingguo Ruan, Xiaolu Yang, Youhai Chen*, and Xiaochun Wan*.TIPE2 Specifies the Functional Polarization of Myeloid-derived Suppressor Cells during Tumorigenesis. J Exp Med. 217(2): e20182005, 2020.
5. Qian Chen, Dehong Yan, Qingmei Zhang, Guizhong Zhang, Meng Xia, Junxin Li, Wugen Zhan, Enyun Shen, Zhihuan Li, Lilong Lin, Youhai H Chen*, Xiaochun Wan*. Treatment of acetaminophen-induced liver failure by blocking the death checkpoint protein TRAIL. Biochim Biophys Acta Mol Basis Dis. 1866 (1): 165583, 2019.
6.Qian Chen, Pu Wang, Qingmei Zhang, Meng Xia, Guizhong Zhang1, Junxin Li, Enyun Shen, Youhai H. Chen* and Xiaochun Wan*. Preclinical studies of a death receptor-5 fusion protein that ameliorates acute liver failure and inflammation. Journal of Molecular Medicine 97(9):1247-1261, 2019.
7. Svetlana A Fayngerts, Zhaojun Wang, Ali Zamani, Honghong Sun, Amanda E Boggs, Thomas P Porturas, Weidong Xie, Mei Lin, Terry Cathopoulis, Jason R Goldsmith, Anastassios Vourekas, Youhai H Chen. Direction of leukocyte polarization and migration by the phosphoinositide-transfer protein TIPE2. Nat Immunol. 18(12): 1353-1360, 2017.
8. Svetlana A Fayngerts, Jianping Wu, Camilla L Oxley, Xianglan Liu, Anastassios Vourekas, Terry Cathopoulis, … Yigong Shi, Youhai H Chen. TIPE3 is the transfer protein of lipid second messengers that promote cancer. Cancer Cell 26(4): 465-78, 2014.
9. Yael Gus-Brautbar, Derek Johnson, Li Zhang, Honghong Sun, Peng Wang, Shirley Zhang, Lining Zhang, Youhai H Chen. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell. 45(5):610-8, 2012.
10. Qingguo Ruan, Vasumathi Kameswaran, Yan Zhang, Shijun Zheng, Jing Sun, Junmei Wang, Jennifer DeVirgiliis, Hsiou-Chi Liou, Amer A Beg, Youhai H Chen. The Th17 immune response is controlled by the Rel-RORγ-RORγ T transcriptional axis. J Exp Med. 208(11):2321-33, 2011.
11. Li Li, Qingguo Ruan, Brendan Hilliard, Jennifer Devirgiliis, Michael Karin, Youhai H Chen. Transcriptional regulation of the Th17 immune response by IKK(alpha). J Exp Med. 208(4):787-96, 2011.
12. Qingguo Ruan, Ting Wang, Vasumathi Kameswaran, Qin Wei, Derek S Johnson, Franz Matschinsky, Weiyun Shi, Youhai H Chen. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U S A. 108(29):12030-5, 2011.
13. Ruan, Q., V. Kameswaran, Y. Tone, L. Li, H-C. Liou, M.I. Greene, M. Tone, Y.H. Chen. Development Of Foxp3+ Regulatory T Cells Is Driven By The c-Rel Enhanceosome. Immunity 31: 932-940, 2009.
14. Ludwinski, M.W, J. Sun, B. Hilliard, S. Gong, F. Xue, R. J. Carmody, J. DeVirgiliis, Y. H. Chen. Critical Roles of Bim in T Cell Activation and T Cell-mediated Autoimmune Inflammation. Journal of Clinical Investigation 119: 1706-1713, 2009.
15. Sun, H., S. Gong, R. J. Carmody, A. Hilliard, L. Li, J. Sun, L. Xu, B. Hilliard, S. Hu, H. Shen, X. Yang, Y. H. Chen. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133: 415-426, 2008.
16. Carmody, R. J., Q. Ruan, S. Palmer, B. Hilliard, Y. H. Chen. Negative regulation of Toll-like receptor signaling by NF-kB p50 ubiquitination blockade. Science 317(5838): 675-678, 2007.
17. Zheng, S., P. Wang, Y. H. Chen. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. Journal of Clinical Investigation 113:58-64, 2004.
18. Lamhamedi-Cherradi, S-E., S. Zheng, K. Maguschak, J. Peschon, Y. H. Chen. Defective Thymocyte Apoptosis and Accelerated Autoimmune Diseases in TRAIL-/- Mice. Nature Immunology 4: 255-260, 2003.
19. Hilliard, B., N. Mason, L. Xu, J. Sun, S-E. Lamhamedi-Cherradi, H-C Liou, C. Hunter, Y. H. Chen. Critical Roles of c-Rel in Autoimmune Inflammation and Helper T Cell Differentiation. Journal of Clinical Investigation 110: 843-850, 2002.
20. Song, K., Y. Chen, R. Göke, A. Wilmen, C. Seidel, A. Göke, B. Hilliard, Y. H. Chen. Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression. Journal of Experimental Medicine 191: 1095-1103, 2000.
21. Chen, Y.H., V.K. Kuchroo, J-I. Inobe, J.L. Baron, C.A. Janeway, H.L. Weiner: Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proceedings of the National Academy of Sciences U.S.A. 93: 388-391, 1996.
22. Chen, Y.H., J-I. Inobe, R. Marks, P. Gonnella, V. K. Kuchroo, H. L.Weiner: Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376: 177-180, 1995.
23. Chen, Y.H., J-I. Inobe, V.K. Kuchroo, D.A. Hafler, H.L. Weiner: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237-1240, 1994.
Patents
(1) T细胞介导的炎症在皮肤疾病的口服耐受,发明,1994,第2作者,专利号:08/486190
(2) RAIL,一种自身免疫性炎症和细胞周期进程抑制剂,发明,2000,第1作者,专利号:766984
(3) REL的抑制剂及其使用方法,发明,2008,第1作者,专利号:PCT/US2009/030325
(4) 使用口服耐受抑制TH1和TH2免疫反应来抑制抗体的产生,发明,1995,第1作者,专利号:08/465592
(5) 基因治疗病毒载体的免疫耐受方法,发明,1997,第1作者,专利号:6211160
(6) TRAIL,一种自身免疫性炎症和细胞周期进程抑制剂,发明,2000,第1作者,专利号:60/157222
(7) 人sDR5蛋白作为乙型病毒性肝炎治疗药物的应用,发明,2006,第1作者,专利号:200610044672.8
(8) REL INHIBITORS AND METHODS OF USE THEREOF, 2013, USA Patent Number US8609730B2.
(9) Treatment of autoimmune psoriasis with c-Rel-specific siRNA, 2016, PCT Patent Number WPI15CN0190X.
Research Interests
Pathogenesis and treatment of cancer, inflammatory and autoimmune diseases